Results of an RF Pulsed Heating Experiment at SLAC

Results are reported from an experiment on RF pulsed heating of copper at SLAC. Damage in the form of cracks may be induced on the surface after the application of many pulses of RF. The experiment consists of two circularly cylindrical cavities operated in the TE011 mode at a resonant frequency of 11.424 GHz. Each cavity received 8.5 MW, 1.2 microsecond pulses at 60 Hz corresponding to a calculated temperature rise of 120 K on the copper surface. After 5.5 x 10^7 pulses, the experiment was stopped and the copper surfaces were examined. Damage is present on the area of the surface where the maximum heating occurred.Comment: 3 pages, 7 figures, Presented at LINAC 2000 conference, Paper ID THA1

In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.

Female C3H/HeJ mice bearing intramuscularly transplanted KHT sarcomas were treated with a single dose of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, 30 mg/kg, i.p.) alone or in combination with a single dose of misonidazole (MISO, 1.0 mg/g, i.p.) or its desmethylated metabolite Ro-05-9963 (2.0 mg/g, i.p.). The effectiveness of drug therapy was assessed by a tumour growth-delay assay (i.e. measuring the median time required for tumours to grow to treatment size x 4). The relative efficacy of administering the nitroimidazoles in various schedules ranging from 12 h before to 12 h after BCNU administration also was evaluated. Untreated control KHT tumours grew to the initial size x 4 in a median time of 4 days. No significant growth delay was seen in mice treated with either nitroimidazole alone, whilst treatment with BCNU alone produced a median growth delay of 7 days. Combination chemotherapy with 9963 administration 3 h after BCNU significantly increased the median tumour growth delay to 9 days. However, no significant growth delay was produced in any of the other combinations of these agents. The median growth delay was significantly reduced to 5 days when MISO was administered 3 h before BCNU, whereas MISO administered simultaneously 3,6, or 12 h after BCNU significantly enhanced delays ( 9 days). These results indicate that both MISO and 0063 may be combined with conventional therapeutic agents, in this particular case a nitrosourea, to produce an enhanced tumour response. The production of such a response appears to be nitroimidazole as well as schedule dependent